Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (referred to as Scisparc Ltd. in metadata) covers the month of May 2018, with the report dated May 9, 2018. The Company is a foreign private issuer headquartered in Givatayim, Israel, with American Depositary Shares (ADSs) trading on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Strategic Shift: The Board of Directors decided to focus efforts on the American market.
- Delisting from TASE: The Company announced steps to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE).
- Timeline: Under Israeli law, the delisting is expected to occur three months after the announcement, on or about August 9, 2018.
- Share Transfer: Following the TASE delisting, all ordinary shares currently traded on the TASE are expected to transfer to Nasdaq.
Outlook, Risks, and Management Commentary
Management intends to continue filing public reports and making disclosures in accordance with U.S. SEC and Nasdaq rules. The Company noted it will elaborate on specific delisting procedures and exact timelines in subsequent filings. No specific financial risks, contingencies, or unusual items were disclosed in this text.
Investor Verification Checklist
- Confirm the exact date of the TASE delisting once announced by the Company.
- Verify the mechanics of the share transfer from TASE to Nasdaq for existing shareholders.
- Monitor subsequent filings for details on the delisting procedures.
- Review upcoming financial reports for the impact of the strategic shift to the U.S. market.